About Us
NBRLBoston originated from E&E Bio-Research Lab, which started in 2006 at Innovative Incubation Center in NJIT nearby Princeton University by US scientists with more than 10 years of experience in established Bio-pharmaceutical companies. At the beginning , the E&E BRL established the therapeutic antibody, Bio-specific fusion protein and immune cellular therapy technical platform, and developed the therapeutic antibody candidate and immune cellular drug at E&E BRL in NJIT. Later on, we expanded to develop several anti-tumor monoclonal antibody and gene drugs and anti-tumor cell drugs simultaneously at MCA Global BRL in the University of Pennsylvania Science Park in 2008.
In 2011, the team moved to Cambridge/Boston MA and continued to engage on developing anti-tumor immune therapy candidates by focusing on anti-solid tumor immune cellular drug and technology development (JaBioUS), and anti-cancer immune gene and intrabody drugs development in New Bio-Research Lab Boston (NBRLBoston). Since then, a variety of anti-cancer immune gene drug and intrabody candidates at NBRLBoston for the treatment of solid tumors and viral infection diseases have been developed. In these days, NBRLBoston has built a proprietary, end-to-end AI engine that transforms early disease hypotheses into optimized, clinically viable biotherapeutics. Next-Generation Biotherapeutic Platform: AI-Engineered Single-Domain Antibodies. Unlocking High-Value Oncology Targets via an Investor-Ready, Validated Asset Pipeline. NBRL has bridged the gap between generative AI and scalable, translation-ready therapeutics. By replacing traditional, slow immunization methods with proprietary machine-learning architectures, we design advanced single-domain antibodies VHH against high-value, complex targets in fractions of the traditional timeline.
Our business model is built for rapid value creation, offering a robust pipeline of pre-validated candidates ready for license-out, co-development, and strategic pharmaceutical partnerships.